SIVs are completed for the neurodegenerative disease trial

This month GCT team has completed all scheduled Site Initiation Visits for the phase II, double-blind, placebo-controlled study in patients with mild-moderate Alzheimer’s Disease.

This USA based clinical trial aims to evaluate the safety, tolerability and preliminary efficacy of the investigational product.

GCT is responsible for the full scope of services: project management, site management, monitoring, IRB interactions and regulatory support in the U.S.

Pictured: a PET scanner
Image credit: Jens Maus, in public domain